Shareholders at Iveda (NASDAQ: IVDA) back new warrant issuance plan

Rhea-AI Filing Summary

Iveda Solutions, Inc. reconvened its 2024 Annual Meeting of Stockholders on August 29, 2025, where stockholders approved the issuance of new common stock purchase warrants. A total of 1,409,415 shares entitled to vote, representing 58.5% of the company’s outstanding voting capital stock as of the October 7, 2024 record date, were present in person or by proxy, constituting a quorum.

Stockholders approved Proposal 5 to issue 625,000 Series A Common Stock Purchase Warrants and 625,000 Series B Common Stock Purchase Warrants, each with an exercise price of $3.44 per common share, along with the shares of common stock issuable upon exercise of these warrants. The proposal received 1,253,925 votes for, 121,349 votes against, and 34,141 abstentions.

false 0001397183 0001397183 2025-08-29 2025-08-29 0001397183 IVDA:CommonStockParValue0.00001Member 2025-08-29 2025-08-29 0001397183 IVDA:CommonStockPurchaseWarrantsMember 2025-08-29 2025-08-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) August 29, 2025

IVEDA SOLUTIONS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-41345		20-2222203
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1744 S. Val Vista, Suite 213 Mesa, Arizona		85204
(Address of Principal Executive Offices)		(Zip Code)

(480) 307-8700

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
Common Stock, par value $0.00001		IVDA		The Nasdaq Stock Market, LLC
Common Stock Purchase Warrants		IVDAW		The Nasdaq Stock Market, LLC

Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 29, 2025, Iveda Solutions, Inc. (the “Company”) reconvened its 2024 Annual Meeting of Stockholders (the “Meeting”). At the meeting, 1,409,415 shares of the Company’s common stock entitled to vote at the Meeting, as of the record date of October 7, 2024, were present in person or by proxy, representing 58.5% of the Company’s outstanding voting capital stock and constituting a quorum for the transaction of business.

At the Meeting, a majority of the outstanding shareholders of the Company approved (Proposal 5) the issuance of: (i) 625,000 Series A Common Stock Purchase Warrants at an exercise price of $3.44 per common share; (ii) 625,000 Series B Common Stock Purchase Warrants at an exercise price of $3.44 per common share; and (iii) the shares of the Company’s common stock upon the exercise of such Series A and Series B Warrants. Each proposal is described in more detail in the Company’s Proxy Statement filed with the Securities and Exchange Commission on October 7, 2024.

The voting results of the shares of the Company’s voting stock for the proposal are set forth below:

Proposal 5 – To approve the issuance of the warrants and the shares of common stock underlying the exercise of such warrants:

Votes For		Votes Against		Votes Abstained
1,253,925		121,349		34,141

SIGNATURES

PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.

	IVEDA SOLUTIONS, INC.
Date: August 29, 2025	By:	/s/ David Ly
	Name:	David Ly
	Title:	Chief Executive Officer

FAQ

What did Iveda Solutions (IVDAW) stockholders approve at the reconvened 2024 Annual Meeting?

Stockholders approved Proposal 5, authorizing the issuance of 625,000 Series A Common Stock Purchase Warrants, 625,000 Series B Common Stock Purchase Warrants, and the shares of common stock issuable upon exercise of those warrants.

How many warrants did Iveda Solutions (IVDAW) obtain approval to issue and at what exercise price?

Iveda Solutions obtained approval to issue a total of 1,250,000 common stock purchase warrants, consisting of 625,000 Series A and 625,000 Series B warrants, each with an exercise price of $3.44 per common share.

What were the voting results for Iveda Solutions’ Proposal 5 warrant issuance?

Proposal 5 received 1,253,925 votes for, 121,349 votes against, and 34,141 abstentions from the company’s voting stock.

What level of shareholder participation was recorded at Iveda Solutions’ reconvened 2024 Annual Meeting?

At the reconvened meeting, 1,409,415 shares entitled to vote as of October 7, 2024 were present in person or by proxy, representing 58.5% of Iveda Solutions’ outstanding voting capital stock, which constituted a quorum.

Which securities of Iveda Solutions are listed on The Nasdaq Stock Market?

Iveda Solutions has its Common Stock, par value $0.00001 per share, listed under the symbol IVDA, and its Common Stock Purchase Warrants listed under the symbol IVDAW on The Nasdaq Stock Market LLC.

Who signed the Iveda Solutions (IVDAW) current report related to the warrant approval?

The report was signed on behalf of Iveda Solutions, Inc. by David Ly, the company’s Chief Executive Officer, dated August 29, 2025.